

November 11, 2022



PAVmed to Participate in BTIG Digital Health Forum

NEW YORK--(BUSINESS WIRE)-- [PAVmed Inc.](#) (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that [Lishan Aklog, M.D.](#), PAVmed’s Chairman and CEO, will participate in the *Technologies Ushering in Next-Generation Diagnostics, Therapies, and Surgeries* virtual panel discussion on November 21, 2022 from 12:00 pm to 12:55 pm EST at the BTIG Digital Health Forum. Dr. Aklog will, in part, discuss PAVmed’s majority-owned digital health subsidiary, [Veris Health](#).

In addition, PAVmed will host 1x1 virtual meetings during the forum. Please contact your BTIG representative for access to the panel discussion and to schedule a 1x1 meeting.

About PAVmed

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company which markets the EsoGuard[®] Esophageal DNA Test and EsoCheck[®] Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Lucid operates its own CLIA-certified, CAP-approved molecular diagnostic laboratory, LucidDx Labs and a network of Lucid Test Centers. Another major subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. The product pipeline also includes the CarpX[®] Minimally Invasive Device for Carpal Tunnel Syndrome, EsoCure[™] Esophageal Ablation Device with CalduS[™] Technology, which complements EsoGuard and EsoCheck, NextFlo[™] Intravenous Infusion Set, PortIO[™] Implantable Intraosseous Vascular Access Device, and other earlier stage technologies. For more information on PAVmed, please visit [PAVmed.com](#) and follow PAVmed on [Twitter](#), [LinkedIn](#), and [YouTube](#). For more information on Lucid, please visit [LucidDx.com](#) and follow Lucid on [Twitter](#), and [LinkedIn](#). For detailed information on EsoGuard, please visit [EsoGuard.com](#) and follow EsoGuard on [Twitter](#), [Facebook](#) and [Instagram](#).

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s and Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause

such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; PAVmed's Series Z warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report and Lucid's Registration Statement No. 333-259721 filed with the Securities and Exchange Commission. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20221111005255/en/>

Investors and Media

Adrian K. Miller

PAVmed Inc.

AKM@PAVmed.com

Source: PAVmed Inc.